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Introduction: Accumulating data implicate the CD4+ T cell subset (Th17 cells) in rheumatoid arthritis (RA). IL-17
is an inflammatory cytokine that induces tumor necrosis factor (TNF)α, IL-1β and IL-6, all of which are targets of
biologic therapies used to treat RA. RA patients are well documented to experience more infections than
age-matched controls, and biologic therapies further increase the risk of infection. The Th17/IL-17 axis is vital for
immunity to fungi, especially the commensal fungus Candida albicans. Therefore, we were prompted to examine
the relationship between RA and susceptibility to C. albicans because of the increasing interest in Th17 cells and
IL-17 in driving autoimmunity, and the advent of new biologics that target this pathway.
Methods: We analyzed peripheral blood and saliva from 48 RA and 33 healthy control subjects. To assess
C. albicans-specific Th17 responses, PBMCs were co-cultured with heat-killed C. albicans extract, and IL-17A
levels in conditioned supernatants were measured by ELISA. The frequency of Th17 and Th1 cells was determined by
flow cytometry. As a measure of IL-17A-mediated effector responses, we evaluated C. albicans colonization rates in
the oral cavity, salivary fungicidal activity and levels of the antimicrobial peptide β-defensin 2 (BD2) in saliva.
Results: Compared to controls, PBMCs from RA subjects exhibited elevated baseline production of IL-17A (P = 0.004),
although they had similar capacity to produce IL-17A in response to Th17 cell differentiating cytokines (P = 0.91).
However RA PBMCs secreted less IL-17A in response to C. albicans antigens (P = 0.006). Significantly more RA patients
were colonized with C. albicans in the oral cavity than healthy subjects (P = 0.02). Concomitantly, RA saliva had reduced
concentrations of salivary BD2 (P = 0.02). Nonetheless, salivary fungicidal activity was preserved in RA subjects (P = 0.70).
Conclusions: RA subjects exhibit detectable impairments in oral immune responses to C. albicans, a strongly
Th17-dependent opportunistic pathogen, despite an overall elevated baseline production of IL-17A.Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by symmetric polyarthritis and systemic
inflammation. Accumulating evidence implicates the cyto-
kine interleukin (IL)-17 and CD4+ T-helper type (Th)17
cells in the pathogenesis of RA [1,2]. IL-17 is a proinflam-
matory cytokine that both induces and synergizes with
tumor necrosis factor (TNF) alpha to promote induction
of IL-1β and IL-6 in target cells, culminating in the pro-
duction of factors such as matrix metalloproteinases and
reactive oxygen species that drive erosive arthritis [3].* Correspondence: sig65@pitt.edu; marclevesque01581@gmail.com
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pathogenesis of RA, patients with severe disease exhibit
elevated frequencies of Th17 cells, and clinical responses
to TNFα inhibitors in autoimmune subjects have been
associated with reductions in circulating Th17 cells [4,5].
Whereas heightened immune responses are pathogenic,
RA is paradoxically associated with impaired host defense
to microbes. Epidemiologic studies have consistently dem-
onstrated a higher incidence of infection in RA patients
compared with the normal population, even when the
effects of medications are controlled for [6,7]. The modern
era of targeted anti-cytokine therapies has resulted in pro-
longed steroid-free remissions. To some extent, however,
this remission has come at the cost of increased suscepti-
bility to opportunistic pathogens, highlighting the import-
ance of these cytokines in host defense. Antibodies againsttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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early clinical trials for several autoimmune conditions
including RA, but their potential impact on susceptibility
to infection is poorly defined [8-12].
Candida albicans is a commensal fungus that colonizes
mucocutaneous surfaces including the oral cavity, tra-
cheobronchial tree and gastrointestinal and genitourinary
tracts. The Th17/IL-17A axis is essential for protective
immunity to mucocutaneous candidiasis [13], and most
Candida-responsive T cells are of the Th17 phenotype
[14]. Humans with impaired induction of Th17 cells
(for example, mutations in STAT1, STAT3 or CARD9)
or defects in IL-17A signaling (for example, mutations
in IL17RA or IL17F) are highly susceptible to chronic
mucocutaneous candidiasis – a condition also seen in pa-
tients with circulating antibodies against Th17 cytokines,
such as in autoimmune polyendocrinopathy syndrome-1
or certain thymomas [15,16]. Somewhat surprisingly, Can-
dida infections are not widely reported in RA [17];
however, recent epidemiologic data from patients with in-
flammatory bowel disease demonstrate that TNFα inhibi-
tors increase the risk of oropharyngeal candidiasis (OPC)
at rates similar to mycobacterial infections [18]. Further-
more, the emerging use of biologics targeting Th17 path-
ways is likely to increase the incidence of C. albicans and
other fungal infections [9,19].
Despite the known susceptibility of RA patients to
infections, there is surprisingly limited information on
pathogen-specific host responses in RA, especially to fungi.
Furthermore, many biologics target Th17 cell generation
or effector function, and yet the functional impact of RA
medications on IL-17-dependent host defense is poorly
understood. We therefore sought to evaluate the impact of
RA on Th17 responses to C. albicans.
Methods
Subjects
RA subjects (n = 48) and healthy controls (n = 33) were
recruited from the University of Pittsburgh Rheumatoid
Arthritis Comparative Effectiveness Research Registry.
Clinical and demographic data were then extracted from
the Registry. The University of Pittsburgh institutional
review board approved this study and all subjects pro-
vided written informed consent.
Peripheral blood mononuclear cell cultures
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from whole blood using Lymphocyte Separation
Media (Accurate Chemical and Scientific, Westbury, NY,
USA) and buoyant density centrifugation. PMBC stimu-
lation was performed by seeding 48-well, flat-bottom,
cell culture plates with 500,000 PBMCs ± 1 × 106 heat-
killed (HK) C. albicans (prepared by boiling ~4 × 108C.
albicans cells for 45 minutes) or a Th17 differentiatingcocktail of recombinant human IL-1β (10 ng/ml), re-
combinant human IL-6 (50 ng/ml), recombinant human
IL-23 (20 ng/ml), recombinant human transforming
growth factor beta (TGFβ; 10 ng/ml), recombinant hu-
man IL-2 (24 IU/ml), anti-IL-12 (5 μg/ml) and anti-IL-4
(5 μg/ml) (R&D Systems, Minneapolis MN, USA) [20].
Supernatants were collected after 5 days and were analyzed
in triplicate for IL-17A by enzyme-linked immunosorbent
assay (eBiosciences, San Diego, CA, USA). C. albicans was
prepared by culturing strain CAF2-1 in yeast peptone
dextrose at 30°C overnight with agitation.
Intracellular cytokine staining and flow cytometry
PBMCs were rested overnight in RPMI supplemented
with 10% fetal bovine serum, L-glutamine, non-essential
amino acids, sodium pyruvate, penicillin and streptomycin;
1 × 106 PBMCs were then stimulated for 4 hours with
50 ng/ml phorbol 12-myristate 13-acetate and 1 μg/ml
ionomycin in the presence of Golgi Plug (BD Biosciences,
Franklin Lakes, NJ, USA). Following stimulation, cells were
stained with anti-CD3 Violet 450 (clone UCHT1), anti-
CD4 Per CP Cy 5.5 (clone OKT4), anti-CD45RO APC-H7
(clone UCHL1), anti-CD161 PE (clone DX12), anti-CD8
FITC (clone RPA-T8), interferon gamma (IFNγ) V500
(clone B27) and anti-IL-17A APC (clone N49-653). Intra-
cellular cytokine staining was performed with the Cytofix
Cytoperm kit (BD Biosciences). Data were acquired on a
BD Aria II (BD Biosciences) and were analyzed with FlowJo
(Ashland, OR, USA).
Salivary assays
Saliva samples were collected by expectoration and placed
in a 10× protease inhibitor cocktail (cocktail set III;
Calbiochem/EMD, Gibbstown, NJ, USA), and saliva was
centrifuged for 5 minutes at 550 × g. Baseline oral C. albi-
cans carriage was determined by plating the supernatant
fraction of spun saliva in triplicate on yeast peptone dex-
trose plates with antibiotics (to suppress growth of oral bac-
teria) and C. albicans colony enumeration after incubation
at 30°C for 48 hours. Salivary C. albicans killing was deter-
mined by incubating the salivary supernatant at 37°C with
1 × 106C. albicans cells (strain CAF2-1) (1:1, v/v) for 1 hour
[21]. C. albicans cells were plated in triplicate for col-
ony enumeration. For β-defensin 2 (BD2) assessment, the
supernatant was analyzed using a BD2 enzyme-linked im-
munosorbent assay kit in duplicate or triplicate as volume
allowed (Phoenix Pharmaceuticals, Burlingame, CA, USA).
BD2 concentrations were normalized to the total protein
content of centrifuged saliva, which was measured by the
bicinchoninic acid assay (BioRad, Hercules, CA, USA).
Statistical analysis
Tests for normality and variance were performed on all
datasets, and two-tailed Student’s t tests or nonparametric
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Student’s t tests were used to assess paired samples, and
Fischer’s exact test was used to assess categorical variables.
Correlations were examined using Spearman’s correlation
coefficient. GraphPad Prism 4.0 was used for all statistical
analyses (GraphPad, La Jolla, CA, USA).
Results
T cells from RA patients exhibit impaired Candida
albicans-specific IL-17A responses
We analyzed peripheral blood samples and saliva from
48 RA subjects and 23 healthy control subjects. Demo-
graphic and clinical characteristics of the subjects are
described in Table 1. All RA subjects were receiving
oral disease-modifying anti-rheumatic drugs (DMARDs)
and/or biologic therapy (primarily TNFα antagonists),
with 17% on biologic monotherapy, 44% on oral DMARDs
only and 38% receiving combination therapy. The majority
of RA subjects (75%) were in remission or had low disease
activity with a 28-joint Disease Activity Score <3.1.
To evaluate the impact of RA on specific responses to
C. albicans, we co-cultured fresh PBMCs from RA sub-
jects or healthy controls with 1 × 106 HK C. albicans for
5 days. As controls, PBMCs from the same subjects were
cultured in media alone (to monitor basal IL-17A produc-
tion) or with a cocktail of Th17 differentiating cytokines
(IL-1β, IL-6, IL-23, anti-IL-4 and anti-IFNγ). RA subjects
exhibited higher basal IL-17A production (31.5 pg/ml,
range: 0 to 146.9) than healthy controls (where it was not
detectable) (P = 0.02). During co-culture with Th17 differ-
entiating cytokines, PBMCs from RA subjects and healthy
controls produced similar amounts of IL-17A (mean:
159.6 pg/ml, range: 0 to 636.3 vs. mean: 166.8 pg/ml,
range: 33.7 to 596.4; P = 0.91). In contrast, upon co-
culture with HK C. albicans, PBMCs from RA subjects
produced significantly lower IL-17A than control PBMCsTable 1 Patient characteristics
Rheumatoid
arthritis patients
Healthy
controls
Number 48 33
Age 56 ± 13 43 ± 13
% female 75 43
Disease duration (years) 12 ± 10 –
Cyclic citrullinated
peptide IgG (units)
232 ± 397 –
Rheumatoid factor (IU/ml) 133 ± 236 –
C-reactive protein (mg/dl) 1 ± 1.75 –
Disease activity score 3.1 ± 1.5 –
DMARDs (%) 92% –
TNFα inhibitors (%) 54% –
Prednisone (%) 23% –
DMARD, disease-modifying anti-rheumatic drug; TNF, tumor necrosis factor.(mean: 259.2 pg/ml, range: 0 to 798.9 vs. mean:
508.1 pg/ml, range: 34.8 to 925; P = 0.006) (Figure 1A). In
RA subjects, levels of IL-17A from the basal PBMC cul-
tures correlated with IL-17A levels from the Th17 diffe-
rentiating cocktail cultures (r = 0.57, P = 0.003; Additional
file 1: Figure S1A). Therefore, despite higher basal IL-17A
and a preserved capacity to respond to Th17 differentiat-
ing cytokines, CD4+ cells from RA subjects exhibited
impaired C. albicans-specific Th17 responses, at least as
measured in vitro.
To address the possibility that oral DMARDs and bio-
logics caused altered C. albicans-specific responses, we
stratified the analyses of IL-17A production and Th17 and
Th1 frequencies by medication usage in the RA cohort.
As shown in Figure 1B, there were no detectable dif-
ferences in the capability of PBMCs from RA subjects
treated with different classes of medications to produce
IL-17A under different stimulation conditions (media
alone, HK C. albicans or Th17 differentiation cocktail).
Similarly, there were no significant differences in Th17 or
Th1 cell frequencies in peripheral blood from RA subjects
treated with oral DMARDs alone, biologics alone or
combinations of oral DMARDs and biologics (Figure 1C).
Biologics therefore do not exacerbate the Candida-
specific impairments in DMARD-treated patients.
Rheumatoid arthritis subjects have lower proportions of
Th17 cells compared with healthy controls
Th17 cells are necessary to prevent OPC, as revealed by
a variety of genetic syndromes associated with chronic
mucocutaneous candidiasis [15]. To determine whether
the impaired C. albicans-specific response was due to a
reduced frequency of total circulating Th17 cells, we com-
pared the frequencies of IL-17A+ (Th17 cells) and IFNγ+
(Th1) CD4+ T cells in peripheral blood. RA subjects
exhibited a slightly reduced percentage of Th17 cells com-
pared with controls (0.50 ± 0.05% and 0.67 ± 0.07%, res-
pectively; P = 0.02), and a higher percentage of Th1 cells
(17.33 ± 1.5% vs. 9.85 ± 1.1%; P = 0.002) (Figure 2A).
The majority of Th17 cells in healthy individuals reside in
the CD161+ and effector memory (TEM, CD45RO
+CCR7−)
compartments, which we confirmed in this study (data not
shown). We first looked at total CD161+ and TEM cells, and
found no difference in the frequencies of these populations
between healthy and RA subjects (Figure 2B; P = 0.82 and
P = 0.36, respectively). We then looked at frequencies of
T-effector subsets within these populations. Both RA
subjects and healthy controls showed similar frequen-
cies of Th17 or Th1 cells in the CD161+ compartment
(respectively 1.44 ± 0.55% vs. 1.33 ± 0.11%; P = 0.11;
13.81 ± 1.48% versus 12.79 ± 1.64%; P = 0.66) (Figure 2C).
There were also no differences in the relative distri-
butions of Th17 or Th1 cells in the TEM compart-
ment (respectively 1.21 ± 0.20% vs. 0.98 ± 0.09%; P = 0.32;
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Figure 1 Reduced Candida albicans-induced Th17/IL-17A responses in rheumatoid arthritis. Rheumatoid arthritis (RA) subjects exhibit
impaired Candida albicans-specific T-cell responses compared with healthy controls. (A) Peripheral blood mononuclear cells (PBMCs) from RA
subjects and controls were cultured for 5 days in media ± heat-killed (HK) C. albicans extract or T-helper type (Th)17 differentiating cytokines
(interleukin (IL)-1β, IL-6, IL-23, anti-IL4 and anti-interferon gamma (anti-IFNγ)). IL-17A in cell free culture supernatants was measured by enzyme-linked
immunosorbent assay (Student’s t test). (B) Tumor necrosis factor (TNF) alpha inhibitors do not exacerbate C. albicans-specific T-cell responses
compared with disease-modifying anti-rheumatic drugs (DMARDs). PBMCs were cultured as in (A) with media alone, HK C. albicans extract or Th17
differentiating cytokines. IL-17A production was assessed in the indicated patient subgroups based on medication use (Mann–Whitney U test). (C)
TNFα inhibitors do not alter the fraction of circulating Th17 or Th1 cells in RA subjects with controlled disease. PBMCs from RA subjects and healthy
controls were gated on CD3+CD4+ lymphocytes and were analyzed for expression of IL-17A (Th17) and IFNγ+ (Th1) cells. Data were stratified by medication
use (Mann–Whitney U test).
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Figure 2 Rheumatoid arthritis subjects have a lower proportion of IL-17A+ but a higher proportion of IFNγ+ CD4+ T cells compared
with controls. (A) Circulating T-helper type (Th)17 and Th1 cells. Peripheral blood mononuclear cells (PBMCs) from rheumatoid arthritis (RA)
patients and healthy controls were gated on CD3+CD4+ lymphocytes and were analyzed for expression of interleukin (IL)-17A (Th17 cells) and
interferon gamma (IFNγ; Th1 cells) (Mann–Whitney U test). (B) Circulating CD161+ and TEM cells. PBMCs were gated on CD3+CD4+ lymphocytes
and were analyzed for expression of CD161 and CD45RO (TEM cells) (Mann–Whitney U test). (C) CD161
+IL17A+ population. PBMCs were gated
on CD3+CD4+CD161+ and analyzed for expression of IL-17A and IFNγ (Mann–Whitney U test). (D) TEM IL-17A+ population. PBMCs were gated on
CD3+CD4+CD45RO+ lymphocytes and were analyzed for expression of IL-17A and IFNγ (Mann–Whitney U test).
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http://arthritis-research.com/content/16/1/R5017.49 ± 0.94% vs. 19.14 ± 2.7%; P = 1). As expected, there
was a significant correlation between the frequency of
circulating Th17 cells and IL-17A production during
PBMC co-culture with HK C. albicans (r = 0.412, P = 0.04)
(Additional file 1: Figure S1B). Accordingly, the impaired
in vitro and in vivo pathogen-specific responses in RA
subjects were associated with reductions in total circulat-
ing Th17 cells.
Rheumatoid arthritis patients exhibit reduced IL-17A-
dependent anti-Candida effector responses in the oral
cavity
In the oral mucosa, IL-17A induces antimicrobial proteins
(AMPs) such as BD2 and salivary histatins, which are
central mediators of host defense against C. albicans [22].
Sjögren’s syndrome patients and others with salivary de-
fects are prone to OPC [23]. We previously reported that
Job’s syndrome patients, who are Th17-deficient due to
mutations in STAT3, exhibit enhanced oral colonization
with C. albicans and concordantly reduced C. albicans
killing capacity and salivary BD2 concentrations [21]. Ac-
cordingly, we sought to determine whether anti-Candida
effector responses such as AMP expression in saliva wereC.
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Figure 3 Rheumatoid arthritis subjects have impaired IL-17A-depend
to Candida albicans. (A), (B) Candida albicans colonization in the oral cav
endogenous C. albicans colonization by plating on yeast peptone dextrose
presented as (A) the percent of each cohort that exhibited any oral coloniz
(Fischer’s exact test and Mann–Whitney U test, respectively). (C) Rheumato
levels. BD2 in saliva from the indicated cohorts was determined by enzyme
intact salivary candidacidal activity. Salivary Candida killing was determined by
spun fraction with 106C. albicans (reference strain CAF2-1) for 1 hour at 37°C.
is indicated as the percentage of a PBS control (Student’s t test).impacted in RA subjects. As shown, RA subjects were
more likely to be colonized with C. albicans in the oral
cavity than healthy controls (50% vs. 15%; P = 0.02)
(Figure 3A). The number of C. albicans organisms detec-
ted in saliva was not statistically different between healthy
and RA subjects (P = 0.53; Figure 3B), with some healthy
individuals showing quite high colonization of this com-
mensal microbe. However, RA subjects exhibited signifi-
cantly lower concentrations of salivary BD2 than healthy
controls (1.3 ± 0.18 vs. 2.2 ± 0.42; P = 0.02) (Figure 3C).
There was no evident correlation between Candida
colonization and BD2 levels (data not shown). To deter-
mine whether reduced BD2 levels were associated with a
functional deficit in antifungal immunity, saliva samples
were co-incubated in vitro with a constant number of cells
from a reference strain of C. albicans, and survival of the
fungus was assessed relative to a PBS control. As shown
in Figure 3D, salivary killing activity was similar between
RA subjects and healthy controls (P = 0.70). Thus, while
there were increased colonization rates of Candida and
reduced IL-17A-dependent salivary AMPs, salivary candi-
dacidal function appeared to be preserved in RA subjects,
which is consistent with their clinical resistance to OPC.%
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id arthritis (RA) subjects exhibit reduced salivary β-defensin 2 (BD2)
-linked immunosorbent assay (Student’s t test). (D) RA subjects show
centrifuging saliva to remove endogenous microbes and incubating the
Triplicate samples were plated on YPD for colony enumeration and killing
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In this study, we found that PBMCs from RA patients
showed impaired Candida-induced IL-17A production,
despite overall elevated basal IL-17A production and a
preserved capacity of CD4+ cells to differentiate in res-
ponse to Th17 differentiating cytokines in vitro. The
impaired Candida-specific response was associated with
an increased rate of RA subjects colonized with Candida
as well as reduced expression of BD2, an IL-17A-depen-
dent salivary AMP. Nonetheless, salivary killing activity
against Candida was preserved in RA subjects. Thus,
while there is clearly a trend towards increased suscep-
tibility to C. albicans colonization in RA, much of the
effector antifungal immune response is retained, consist-
ent with the clinical resistance to oropharyngeal candidia-
sis in RA patients.
Genome-wide association study data point to a role
for the Th17/IL-17 axis in RA, as risk alleles impact
Th17 generation and maintenance (IL6R, IL2, IL21,
TYK2), trafficking (CCR6) or IL-17A signal transduction
(TNFAIP3) [24,25]. Clinically, active RA has been associ-
ated with elevated fractions of Th17 cells compared with
healthy controls, and individuals that respond to TNFα
inhibitors are reported to show reductions in Th17
cells compared with nonresponders [4]. Erosive arth-
ritis in most animal models is IL-17A dependent, as
treatment with blocking antibodies ameliorates dis-
ease, and disease induction is mild or absent in IL-17A-
deficient mice [26,27]. Hence, agents that inhibit the Th17
pathway at multiple points, including inhibitors of JAK
kinases, IL-23, IL-17A and IL-17RA, are currently being
used or evaluated in RA and other autoimmune condi-
tions [9,28].
Because the majority of the RA patients in this study
had DMARD-controlled disease, we used this group as a
reference population. An acknowledged limitation is ex-
clusion of treatment-naïve patients with poorly controlled
disease. An ideal follow-up will be to assess longitudinal
pathogen-specific responses, starting before drug treat-
ment is initiated. Nonetheless, these findings are internally
consistent (reduced Th17 cell frequency, reduced IL-17A-
regulated AMP expression, reduced pathogen-induced
IL-17A production) and recapitulate the characteristic
clinical phenotype of RA, where overt susceptibility to
OPC is rarely seen (preserved salivary Candida kill-
ing, minimally elevated oral Candida colonization rates).
Our findings also suggest there may be a threshold effect
of IL-17A in mediating host defense to Candida, where
even low amounts of IL-17A are sufficient for protective
immunity. Our finding that Th17 cells in RA subjects
were reduced relative to controls contrasts with some
prior studies, but may be explained by the fact that these
patients had controlled disease with an average Disease
Activity Score of 3.1 (Table 1).RA patients generally have not been reported to show
a strong susceptibility to C. albicans despite their overall
increased risk for infections [17]. The reasons for this
are unclear, but as only ~50% of patients with Candida
esophagitis have concurrent OPC, it is possible (and
supported by our data; Figure 3) that RA patients may
have elevated rates of subclinical C. albicans colonization,
and hence are poised to more readily progress to clinical
OPC under certain circumstances; for example, targeted
anti-IL-17A therapies. Additionally, innate mechanisms
such as salivary killing capacity may help maintain effect-
ive immunity to C. albicans even in the face of some de-
gree of Th17 depletion (Figure 3). It is unclear whether
RA patients also exhibit impaired or altered responses to
other Th17-dependent pathogens, such as Staphylococcus
aureus or Klebsiella pneumonia, which would be an im-
portant line of investigation to stem from these findings.
Traditionally, candidiasis has not been linked to TNFα
inhibition, but new data suggest that TNFα inhibitors
may in fact increase the risk of OPC [18]. Moreover,
joint pathology can be induced or exacerbated by immu-
nization with antigens found in the cell walls of com-
mensal fungi, such as β-1,3-glucan and zymosan; elevated
C. albicans colonization rates such as we observed in
Figure 3 thus have the potential to exacerbate RA symp-
toms [29]. The increased basal IL-17A production in this
cohort coupled with impaired C. albicans-induced IL-17A
induction (Figure 1A) suggests that patients with RA have
elevated IL-17A production on a per-cell basis yet exhibit
subclinical pathogen-specific impairments. Accordingly,
selective targeting of Th17 pathways may render patients
clinically susceptible to OPC or other mucocutaneous
manifestations of this fungus. Susceptibility could con-
ceivably be additionally heightened if TNFα inhibitors are
used in combination with selective Th17/IL-17 inhibiting
agents, since IL-17 synergizes potently with TNFα [30,31].
Although TGFβ, IL-1β, IL-6 and IL-23 are important
for the lineage commitment and/or function of human
Th17 cells, data from animal models suggest that select-
ive exposure to these cytokines during differentiation
may differentially impact the function of Th17 cells. Ex-
posure to IL-23 in T cells that were previously polarized
by TGFβ and IL-6 drives pathogenic Th17 cells, whereas
a lack of IL-23 results in IL-10-producing Th17 cells that
restrain pathogenic Th17 cells [32,33]. Similarly, the
TGFβ3 isoform induces pathogenic Th17 cells, whereas
the TGFβ1 isoform does not [34]. These data may explain
the paradox in RA of having an excessively active Th17/IL-
17A axis and a simultaneous susceptibility to infections.
That is, patients with RA may have elevated pathogenic
Th17 cells at the expense of protective Th17 cells. In this
regard, the increase in Th1 cells we observed in this study
(Figure 2A) suggests that Th1 cells may not compensate
for a reduced IL-17 response. This would be consistent
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humans with hyper-IgE syndrome have impaired Th17
levels due to STAT3 mutations; these patients have
normal Th1 levels but are nonetheless susceptible to
mucocutaneous candidiasis. Similarly, deficient IFNγ−/− or
IL-12p35−/− mice are resistant to oral and dermal can-
didiasis, whereas IL-23−/− mice and IL-17R−/− mice are
susceptible [35,36].
Conclusions
This study finds that patients with RA exhibit impaired
C. albicans-specific IL-17A production, despite elevated
basal IL-17A serum levels and a preserved capacity for
Th17 cell induction in vitro. These impaired responses
are associated with an increased rate of oral C. albicans
colonization and reduced IL-17A-dependent AMP pro-
duction in saliva. Although mucosal Candida infections
are not a commonly reported side effect associated with
RA, the present data suggest that biologic drugs select-
ively targeting the IL-23/IL-17 axis may increase the risk
of RA patients to mucosal candidiasis.
Additional file
Additional file 1: Figure S1. (A) IL-17A production under Th17
differentiating conditions correlates with baseline IL-17A production.
IL-17A production by PBMC co-cultures with Th17 differentiating cytokines
was correlated to baseline IL-17A production by PBMCs by spearman’s
coefficient. (B) IL-17 production to HK C. albicans correlates with the fraction
of circulating Th17 cells. IL-17A production by PBMCs co-cultured with
HK C. albicans was correlated to the fraction of circulating Th17 cells by
Spearman’s coefficient.
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